Immunosuppressants and risk of Parkinson disease-Reference-Cited by-同舟云学术

Immunosuppressants and risk of Parkinson disease

Published:2018-05-31 Issue:7 Volume:5 Page:870-875
ISSN:2328-9503
Container-title:Annals of Clinical and Translational Neurology
language:en
Short-container-title:Ann Clin Transl Neurol

Author:

Racette Brad A.¹²,Gross Anat¹,Vouri Scott Martin³,Camacho-Soto Alejandra¹,Willis Allison W.⁴⁵⁶,Searles Nielsen Susan¹

Affiliation:

1. Department of Neurology; Washington University School of Medicine; 660 South Euclid Avenue, Campus Box 8111 St. Louis Missouri 63110

2. School of Public Health; Faculty of Health Sciences; University of the Witwatersrand; 7 York Road Parktown 2193 South Africa

3. Center for Health Outcomes Research and Education; Department of Pharmacy Practice; St. Louis College of Pharmacy; 4588 Parkview Place St. Louis Missouri 63110

4. Department of Neurology; University of Pennsylvania Perelman School of Medicine; 423 Guardian Drive Philadelphia Pennsylvania 19104

5. Department of Biostatistics, Epidemiology and Informatics; University of Pennsylvania Perelman School of Medicine; 423 Guardian Drive Philadelphia Pennsylvania 19104

6. The Center for Pharmacoepidemiology Research and Training; University of Pennsylvania Perelman School of Medicine; 423 Guardian Drive Philadelphia Pennsylvania 19104

Funder

Michael J. Fox Foundation for Parkinson's Research

National Institute of Environmental Health Sciences

National Institute of Neurological Disorders and Stroke

American Parkinson's Disease Foundation

University of Pennsylvania

Publisher

Wiley

Subject

Clinical Neurology,General Neuroscience

Reference18 articles.

1. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease;Parkinson Study Group PRECEPT Investigators;Neurology,2007

2. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease;Parkinson Study Group;N Engl J Med,1993

3. A double-blind, delayed-start trial of rasagiline in Parkinson's disease;Olanow;N Engl J Med,2009

4. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease;Olanow;Ann Neurol,2003

5. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial;Kieburtz;JAMA,2015

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Update: Protective and risk factors for Parkinson disease;Parkinsonism & Related Disorders;2024-08

2. Lysosomal storage, impaired autophagy and innate immunity in Gaucher and Parkinson's diseases: insights for drug discovery;Philosophical Transactions of the Royal Society B: Biological Sciences;2024-02-19

3. Cortistatin as a Novel Multimodal Therapy for the Treatment of Parkinson’s Disease;International Journal of Molecular Sciences;2024-01-05

4. The pathogenesis of Parkinson's disease;The Lancet;2024-01

5. Association Between Use of Any of the Drugs Prescribed in Norway and the Subsequent Risk of Parkinson Disease;Neurology;2023-11-21